Genmab and AbbVie Complete Enrollment in Phase 3 Epcoritamab DLBCL Trial in China, Accelerating Approval Prospects
Accelerating Market Entry in China and Clinical Background
Genmab and AbbVie have completed enrollment of 72 patients in their pivotal Phase 3 trial (NCT07226752) in China for epcoritamab, a bispecific antibody they are co-developing. This trial aims to demonstrate superiority compared to standard chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). China represents one of the largest global markets for lymphoma patients, and regulatory reforms are rapidly accelerating the approval of innovative new drugs. Therefore, the success of this trial is expected to be a critical turning point for establishing a presence and expanding commercially within the Asian market.
Limitations of Existing Standard Treatments and the Mechanism of Action of Bispecific Antibodies
Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options, as they often do not respond to standard chemotherapy regimens (R-GemOx or BR) or are ineligible for autologous stem cell transplantation (ASCT). Epcoritamab is a bispecific antibody that simultaneously targets CD20 on B cells and CD3 on T cells, activating the patient's own immune T cells to directly kill cancer cells. Unlike Roche's Columvi (glofitamab), which is administered intravenously, epcoritamab is administered via subcutaneous injection (SC), enhancing convenience and reducing adverse effects at the injection site. This superior mechanism addresses a significant unmet need in terms of improving patient compliance and tolerability in clinical practice.
Global Regulatory History and China Approval Roadmap
Epcoritamab has already received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2023 as a third-line treatment for R/R DLBCL, and in June 2024, its indication was expanded to include follicular lymphoma (FL). The China National Medical Products Administration (NMPA) granted initial approval for the R/R FL indication on May 15, 2026; however, the larger DLBCL indication had a New Drug Application (NDA) submitted in November 2024 and is currently under active review. The data from this Phase 3 substudy in China will serve as key evidence supporting the efficacy and safety profile in Chinese patients and will be a strong asset in influencing the NMPA's final approval decision. Approval would likely position epcoritamab as the first targeted bispecific antibody for DLBCL in China.
Large-Scale Partnership and Financial Expectations
Genmab and AbbVie entered into a major oncology co-development agreement in June 2020, with a total value of $3.9 billion ($750 million upfront and $3.15 billion in milestones), to jointly develop and commercialize products globally. AbbVie is responsible for sales in all markets except the U.S. and Japan, and Genmab receives tiered royalties ranging from 22% to 26% of sales. With the global DLBCL treatment market projected to grow to approximately $7.54 billion by 2030, establishing a strong presence in the Chinese market will undoubtedly contribute significantly to the financial performance of both companies. The success of this Phase 3 trial will be a key indicator of the long-term profitability of the partnership.
Genmab and AbbVie's co-developed epcoritamab has received approval from the U.S. FDA and China's NMPA for follicular lymphoma (FL) treatment, and they are now actively initiating a Phase 3 clinical trial for diffuse large B-cell lymphoma (DLBCL), a more prevalent indication, in China. In response to Roche's Columvi (glofitamab), which leverages a fixed-duration administration schedule, epcoritamab aims to capture a portion of the approximately $7.54 billion global DLBCL market by maximizing the convenience of subcutaneous (SC) administration. In the short term, the NMPA's review of the New Drug Application (NDA) submitted in November 2024 is expected to be completed, and the successful outcome of this trial will be pivotal in determining approval. In the long term, this will maximize the potential of the large-scale deal, valued at $750 million upfront and $3.15 billion in milestones, and drive revenue growth through royalties ranging from 22% to 26% from commercialization outside of China. From the perspective of clinical researchers and industry professionals, this will be a turning point in revolutionizing local treatment paradigms for hematological malignancies by providing a new therapeutic option for patients with relapsed disease who are ineligible for autologous stem cell transplantation (ASCT).
Source: ClinicalTrials.gov (api_ct)